Theravance Biopharma Stock Forecast

Stock Price Forecast

The 5 analysts with 12-month price forecasts for Theravance Biopharma stock have an average target of 20.2, with a low estimate of 14 and a high estimate of 27. The average target predicts an increase of 47.82% from the current stock price of 13.67.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$14	$20.2	$21	$27
Change	+2.45%	+47.82%	+53.68%	+97.59%

Analyst Ratings

The average analyst rating for Theravance Biopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	4	4	4	4	4	3
Buy	0	0	1	1	1	1
Hold	0	0	0	0	0	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $27 → $15	Strong Buy	Maintains	$27 → $15	+9.77%	Mar 4, 2026
Mayank Mamtani B. Riley Securities	B. Riley Securities	Strong Buy → Hold Downgrades $28 → $14	Strong Buy → Hold	Downgrades	$28 → $14	+2.45%	Mar 4, 2026
Julian Harrison BTIG	BTIG	Strong Buy Maintains $40 → $21	Strong Buy	Maintains	$40 → $21	+53.68%	Mar 3, 2026
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $20 → $27	Strong Buy	Maintains	$20 → $27	+97.59%	Mar 2, 2026
Julian Harrison BTIG	BTIG	Strong Buy Reiterates $40	Strong Buy	Reiterates	$40	+192.72%	Feb 3, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

110.03M

from 64.38M

70.90%

from 64.38M

Revenue Next Year

102.77M

from 110.03M

-6.60%

from 110.03M

EPS This Year

1.93

from -1.15

EPS Next Year

0.96

from 1.93

-50.18%

from 1.93

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	71.86M	55.31M	51.35M	57.42M	64.38M	110.03M	102.77M
Revenue Growth	-2.12%	-23.03%	-7.17%	11.84%	12.12%	70.90%	-6.60%
EPS	-4.46	-2.87	11.85	-1.00	-1.15	1.93	0.96
EPS Growth	-	-	-	-	-	-	-50.18%
Forward PE	-	-	-	-	-	7.06	14.18
No. Analysts	-	-	-	-	-	9	9

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	114.0M	193.5M
Avg	110.0M	102.8M
Low	105.1M	80.4M

Revenue Growth

Revenue Growth	2025	2026
High	77.1%	75.9%
Avg	70.9%	-6.6%
Low	63.2%	-27.0%

EPS Forecast

EPS	2025	2026
High	2.37	1.37
Avg	1.93	0.96
Low	1.37	0.19

EPS Growth

EPS Growth	2025	2026
High	-	-29.4%
Avg	-	-50.2%
Low	-	-90.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.